A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT06131840. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label Phase 1 Study to Investigate PF-08046050 (SGN-CEACAM5C) in Adults With Advanced Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to treat. Participants in this study must have cancer that has come back or did not get better with treatment. Participants must have a solid tumor cancer that can't be treated with standard of care drugs. This clinical trial uses an experimental drug called PF-08046050. PF-08046050 is a type of antibody-drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. They may also stick to some normal cells. This study will test the safety of PF-08046050 in participants with solid tumors that are hard to treat or have spread throughout the body. This study has 5 different study parts. Part A and Part B of the study will find out how much PF-08046050 should be given to participants. Part C will use the information from Parts A and B to see if PF-08046050 is safe and if it works to treat certain solid tumor cancers. Part D and E of the study, together with information from Parts A and B, will find out how much PF-08046050 should be given in combination with other anti-cancer agents. Part E will use the information from Parts A, B, and D to see if PF-08046050 is safe in combination with other anti-cancer agents and if it works to treat a certain solid tumor.
Study identification
- NCT ID
- NCT06131840
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 914 participants
Conditions and interventions
Conditions
Interventions
- PF-08046050 Drug
- bevacizumab Drug
- 5-Fluorouracil (5-FU) Drug
- Oxaliplatin Drug
- Leucovorin (LV) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 19, 2023
- Primary completion
- Sep 11, 2029
- Completion
- Sep 11, 2030
- Last update posted
- Jul 21, 2026
2023 – 2030
United States locations
- U.S. sites
- 21
- U.S. states
- 12
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Hospital | Phoenix | Arizona | 85054 | Recruiting |
| Mayo Clinic | Scottsdale | Arizona | 85259 | Recruiting |
| City of Hope (City of Hope National Medical Center, City of Hope Medical Center) | Duarte | California | 91010 | Recruiting |
| IP Address: City of Hope Investigational Drug Services(IDS) | Duarte | California | 91010 | Recruiting |
| University of Colorado Hospital - Anschutz Cancer Pavilion (ACP) | Aurora | Colorado | 80045 | Recruiting |
| University of Colorado Hospital | Aurora | Colorado | 80045 | Recruiting |
| Florida Cancer Specialists | Orlando | Florida | 32827 | Recruiting |
| Sarah Cannon Research Institute at Florida Cancer Specialists | Orlando | Florida | 32827 | Recruiting |
| Sidney Kimmel Comprehensive Cancer at Johns Hopkins | Baltimore | Maryland | 21287 | Recruiting |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | Recruiting |
| START Midwest | Grand Rapids | Michigan | 49546 | Recruiting |
| Mayo Clinic Cancer Center | Rochester | Minnesota | 55905 | Recruiting |
| Mayo Clinic | Rochester | Minnesota | 55905 | Recruiting |
| MidAmerica Cancer Care | Kansas City | Missouri | 64132 | Not yet recruiting |
| Sarah Cannon Research Institute - Pharmacy | Nashville | Tennessee | 37203 | Recruiting |
| SCRI Oncology Partners | Nashville | Tennessee | 37203 | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
| NEXT Dallas | Irving | Texas | 75039 | Not yet recruiting |
| South Texas Accelerated Research Therapeutics, LLC | San Antonio | Texas | 78229 | Recruiting |
| START Mountain Region | Salt Lake City | Utah | 84119 | Recruiting |
| South Texas Accelerated Research Therapeutics Mountain Region | West Valley City | Utah | 84119 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06131840, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 21, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06131840 live on ClinicalTrials.gov.